Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

INTRODUCTION: Treatment with selective serotonin reuptake inhibitors has been suggested to mitigate amyloid-β (Aβ) pathology in Alzheimer's disease, in addition to an antidepressant mechanism of action. METHODS: We investigated whether chronic treatment with paroxetine, a selective serotonin re...

Descripción completa

Detalles Bibliográficos
Autores principales: Severino, Maurizio, Sivasaravanaparan, Mithula, Olesen, Louise Ø., von Linstow, Christian U., Metaxas, Athanasios, Bouzinova, Elena V., Khan, Asif Manzoor, Lambertsen, Kate L., Babcock, Alicia A., Gramsbergen, Jan Bert, Wiborg, Ove, Finsen, Bente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021554/
https://www.ncbi.nlm.nih.gov/pubmed/29955664
http://dx.doi.org/10.1016/j.trci.2018.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021554/
https://www.ncbi.nlm.nih.gov/pubmed/29955664
http://dx.doi.org/10.1016/j.trci.2018.04.005

Ejemplares similares